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THE TREATMENT OF RHEUMATIC CARDITIS: SALICYLATES vs. STEROIDS 
For the past twenty years, the treatment of rheumatic fever has 
evolved around two drugs, salicylates and steroids. During this time, 
a great deal of literature and controversy has accumulated concerning 
the relative merits of these two therapeutic approaches. It has been 
generally appreciated that both drugs are effective in controlling joint 
symptomatology, fever and other toxic manifestations of the disease. 
However for the most part rheumatic fever is a self-limited disease, and 
carditis is the only rheumatic manifestation which results in sequelae. 
Thus, it is the treatment of rheumatic carditis and the prevention of 
residual heart disease that has primarily concerned investigators in the 
field. 
Salicylates were first popularized for the treatment of rheumatic 
13 fever in 1876 by Maclagan. His remedy was extracted from the bark of 
a willow belonging to the Salicaceae family. Following his discovery, 
salicylates in varying dosages became immensely popular in the treatment 
of rheumatic fever. It was not until 1949 when Hench lO introduced ster-
oids to rheumatic therapy that the superiority of salicylates was chal-
lenged. Subsequently numerous contradictory reports concerning the 
advantages and limitations of these two therapeutic regimens were pub-
lished and the need for a carefully controlled study became essential. 
Clinical trials of therapeutic agents for a disease as unpredictable 
and variable as rheumatic fever are beset with many pitfalls, which may 
invalidate the findings. 23 Stollerman in his review of the subject re-
marked, lilt should be obvious that the variables involved in matching 
"-"" u 
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-groups of patients to therapeutic trials are so numerous that few 
studies can satisfy all criticism of their design.'!) Many factors must 
be taken into consideration. In order to exclude the possibility of 
previous injury to the heart, a complete history is essential to confirm 
that the rheumatic episode represents a first attack. Furthermore, the 
symptoms must be of relatively short duration, otherwise irreversible 
changes may have occurred before treatment is initiated. Secondly, the 
drugs must be administered concurrently to prove the superiority of one 
over the other. Results obtained in studies undertaken in previous years 
cannot be used for comparison as it appears that the severity of rheuma-
tic fever is declining and its pattern changing. 19 Thirdly, cardiac 
status at the time therapy is instituted must be strictly defined and 
treatment groups must be comparable as to severity of carditis. Patients 
with mild carditis should be excluded, because irrespective of therapy 
they tend to recover without residual heart disease. 26 Finally, to in-
sure complete objectivity, patients must be allocated to their respective 
treatment groups on a blind and random basis. 
It is the purpose of this paper to review and criticize the various 
controlled studies concerning the treatment of rheumatic carditis. Em-
phasis will be placed on the U.K. and U.S. Cooperative Report as it is 
very comprehensive and represents a model clinical trial. Therapeutic 
concepts will be summarized and a program of rheumatic therapy proposed. 
In 1950, when steroids became available the need for a controlled study 
was apparent in order to obtain definitive information on the value of 
these drugs in the treatment of rheumatic fever. Twelve research centers 
in Great Britain, Canada and the United States embarked on a cooperative 
study under the sponsorship of the American Heart Association, and the 
Medical Research Council of Great Britain. 25 The study was designed 
to compare the therapeutic effects of the hormones, ACTH and cortisone. 
with the usual treatment of rheumatic fever at the time. Answers were 
to be sought to two questions: (1) What is the relative effectiveness 
of each of these hormones and of aspirin in altering the course of the 
acute disease in suppressing its clinical manifestations? (2) What is 
the relative effectiveness of these three agents in preventing rheumatic 
heart disease? 
Only children under 16 years of age who met the modified Jones cri-
teria (1955) for the diagnosis of rheumatic fever were included in the 
study. In all, 497 patients were accepted and allocated at random to 
treatment with one of the three drugs - ACTH, Cortisone or Aspirin. Each 
regimen was given for six weeks according to a defined schedule and de-
tailed observations were continued for an additional three weeks. Follow-
up examinations were made at specific times after these nine weeks, and 
the first report extended one year from the initial nine weeks. 
DOSAGE SCHEDULES OF U.K. AND U.S. REPORT 
DRUG DAILY DOSE DAY OF TREATMENT 
Acety1salic;:ylic Acid 60 mg/1b 1-2 
40 mg/1b 3-7 
30 mg/1b 8-42 
Cortisone 300 mg 1 
200 mg 2-5 
100 mg 6-21 
75 mg 22-35 
50 mg 36-42 
ACTH U.K CASES U.S. CASES 
80 USP units 120 USP units 1-4 
60 USP units 100 USP units 5-7 
40 USP units 8-21 
80 USP units 8-14 
60 USP units 14-21 
30 USP units 40 USP units 22-35 
20 USP units 20 USP units 36-42 
-. 
As will be noted, many critics of this study considered the hormone 
dosages too small and the treatment period too short. On the other hand, 
nearly all cases receiving hormones developed Cushingoid cosmetic effects. 
All patients received penicillin to maintain therapeutic levels for 
14 days to eradicate streptococci foci, followed by oral sulfadiazine to 
prevent intercurrent streptococcal infections during the hospital stay and 
throughout the follow-up period. All patients were kept at bed rest for 
the nine weeks of therapy and observation. 
The three treatment groups were further subdivided into three groups 
according to the length of time of each case between the date of onset of 
the attack and the date at which therapy began. The three duration - from -
onset groups were (1) 14 days or less; (2) 15-42 days; (3) 43 days and 
over. Of the 497 cases, just over half (255) began therapy within 14 days 
within onset of the attack and 60 per cent of these (149) were treated 
wi thin one week of ons e t. In near ly two- thi rds (327) there was nei t-her 
history of a previous attack of rheumatic fever, or evidence of pre-existing 
rheumatic heart disease. Approximately one-fourth (128) of the 497 cases 
were definitely diagnosed as having pre-existing rheumatic heart disease 
at the start of therapy. 
Random construction of the three treatment groups caused them to be re-
markably similar in many aspects such as; the treatment - from - onset pe-
riod, age, sex, weight, temperature, pulse during sleep, erythrocyte sedi-
mentation rate (ESR), frequency of polyarthritis, incidence of subcutan-
eous nodules, incidence of erythema marginatum, and incidence of basal 
diastolic murmurs. However, two differences exist: (1) The aspirin group 
included more patients with chorea as a presenting symptom (15.5%) than ACTH 
(5.6%) and cortisone 01.4%) (2) The ACTH group had a larger proportion 
of severe carditis represented by congestive heart failure and/or peri-
carditis. Such cases numbered 27 for ACTH, 24 for cortisone and 17 for 
aspirin. The fact that fewer cases of severe carditis were present in 
the aspirin group has also been criticized by those who maintain that 
differences in drug effectiveness are most evident in very severe car-
d " . 4 l.tl.S. It is also noted that four cases in the aspirin group were 
eventually administered hormone treatment because of the severity of 
their illness. Statistically, these four cases remain in the aspirin 
group but' are none the less indicative of some investigator bias con-
cerning the treatment of severe cases. 
During the acute illness and the first year follow-up, six deaths 
occurred, one in the ACTH, two in the cortisone and three in the aspirin 
group. Two of the three aspirin deaths were switched to hormone therapy 
prior to death. Apart from the six deaths, there were some in each 
group who, during the one year period, were retreated for persisting 
or recurring manifestations. Retreatment was given to 10 of the 161 
ACTH cases surviving to one year, 8 of the 165 cortisone cases surviving 
to one year, and 19 of 165 aspirin cases surviving to one year. However 
further analysis of these cases shows that the greater proportion of 
retreatment in the aspirin group occurred primarily among the chronic 
cases (43 days or more between onset and treatment) and was influenced 
by the larger number of cases initially admitted with chorea to the 
aspirin group. 
It is important to note that practically all the ACTH and cortisone 
cases showed one, or a combination. of the following side effects of 
therapy: moonface, hirsutism, acne or stria. There were only 10.5% 
of the ACTH and 4.8% of the cortisone without any of these side effects 
by the end of the ninth week. In addition to these side effects many 
others were reported, but not tabulated. These included cases of hyper-
tension, mental symptoms, convulsions, renal hemorrhage, water and salt 
retention, glycosuria, infections, hepatomegaly, febrile reactions, 
pigmentation, increased fat deposition and unusual increase in appetite. 
Furthermore relatively few aspirin cases developed side effects. There 
were 26.7% of the aspirin group that developed side effects such as 
tinnitus or deafness, nausea or hyperventilation. These side effects 
all appeared in the first week of therapy while the aspirin dosage was 
relatively high and promptly disappeared when the dosage was reduced. 
The report concluded that: (1) The temperature and pulse rate 
during sleep returned to normal during treatment in the great majority 
of cases in all treatment groups, but there was a greater tendency in 
the groups treated with the hormones for them to become elevated in the 
6-9 week observation period. (2) The erythrocyte sedimentation rate 
decreased more rapidly during treatment in the hormone treated group 
but was elevated more frequently in the 6-9 week observation period. 
There were no differences between treatment groups at the thirteenth 
week. The temperature, pulse and ESR re-elevation during the observa-
tion period was later termed "rebound phenomena." (3) The behavior of 
joint involvement, chorea and erythema marginatum was essentially the 
same in the three treatment groups. Nodules, however, disappeared 
more rapidly in the patients treated with hormones although new nodules 
appeared in some patients during treatment in all three groups. 
In the evaluation of the cardiac status of their cases, the study 
used the parameters of heart size, PR interval, murmurs and congestive 
heart failure, and/or pericarditis. Cases were further subdivided into 
three cardiac groups: (A) those without pre-existing heart disease 
or current carditis; (B) those currently with carditis but without 
pre-existing heart disease; (C) those with pre-existing heart disease. 
The study reported that when heart size was measured by the pro-
portion of patients with a cardiothoracic ratio of .55 or more, the 
cardiac subgroups and the total cases revealed no differences between 
treatment up to and including the one year follow-up period. The PR 
intervals decreased more frequently and rapidly in the hormone groups 
than in the aspirin group. This difference lessened during the obser-
vation period and was absent at nine weeks and one year. It may be 
questioned whether the early decrease in PR intervals in an effect of 
the hormones on the disease or merely a direct effect on the atrio-
ventribular conduction time. Also, it was reported that there appeared 
to be no relationship between treatment groups and the appearance or 
disappearance of congestive heart failure and pericarditis. 
Concerning murmurs, findings indicated: (1) The development of 
an apical systolic murmur, or basal diastolic murmur among those with-
out such murmurs at the start of therapy, regardless of the presence 
or absence of carditis, was infrequent and not related to therapy. 
(2) The disap~earance of soft apical systolic murmurs was more rapid 
among the hormone groups than among those receiving aspirin, but at the 
end of one year the treatment groups did not differ significantly. 
(3) The disappearance or diminution of loud apical systolic murmurs 
rarely occurred regardless of therapy. (4) At the end of one year there 
was no evidence that the treatment groups differed in the frequency with 
which murmurs had appeared or disappeared. 
In summary, the report concluded that there was no evidence that 
any of the three agents resulted in uniform termination of the disease. 
Treatment with either of the hormones resulted in more prompt control 
of certain acute manifestations, but this more rapid disappearance was 
balanced by a greater tendency for the acute manifestations to reappear 
for a limited period upon cessation of treatment (rebound phenomena). 
Treatment with the hormones also leads to the more rapid disappearance 
of nodules and of soft apical systolic murmurs. However at the end of 
one year, there was no significant difference between the treatment 
groups in the status of the heart. 
In October 1960, the five year report of the U.K and U.S. Coopera-
26 tive Clinical Trial was published. At this time, 445 of the original 
497 cases were known to be alive (89.5%) and 16 were known to have died 
(3.2%). Thus 92.7% of the 497 cases were traced at 5 years. The find-
ings of the report confirmed those reported at one year, in that there 
was no appreciable difference in the cardiac status of the three treat-
ment groups, and thus the prognosis had not been influenced by one treat-
ment more than another. The Report was however, able to definitely cor-
relate cardiac prognosis with the status of the heart at the time treat-
ment was initiated. For cases without carditis initially the prognosis 
was excellent since in 96% there was no residual heart disease. In 
cases with carditis initially but without pre-existing heart disease 
the proportion without residual heart disease decreased progressively 
from 82% for those with only a grade I apical systolic murmur to 30% for 
those with failure and/or pericarditis. In cases with pre-existing heart 
disease the prognosis was poor. Only 30% of those without pericarditis 
or failure and none of those with pericarditis or failure were without 
heart disease at 5 years. Most of the deaths from rheumatic fever 
(10 of 14) occurred among cases with pre-existing heart disease and 
there were no deaths among the cases without heart involvement at 
the beginning of treatment. All in all, the report concluded that 
the treatment of rheumatic fever cannot be properly evaluated unless 
the cardiac status at the start of therapy is taken closely into ac-
count as this is probably the most important factor in the prognosis. 
27 In September 1965, the ten year report was released. Three 
hundred and ninety-seven cases <79.9%) were known to be alive at ten 
years and 19 (3.8%) were known to have died from rheumatic fever or 
rheumatic heart disease. Again, it was confirmed that prognosis had 
not been influenced by treatment and that the initial cardiac status 
was the most important prognostic factor. It was also noted that the 
fatality rate was very low in each of the groups, indicating that the 
patients had done well regardless of treatment. 
Following the Cooperative Study, numerous reports were published 
advocating the superiority of steroids in the treatment of rheumatic 
carditis. For the most part, these studies were uncontrolled and based 
on the premise that the steroid dosage of the Cooperative Study had been 
too low and administered for too short a time. Greenman and his co-
9 
workers (1952) were among the first to report good results with 300 mg. 
of cortisone given daily for 6 to 8 weeks to patients in their initial 
attacks of rheumatic carditis. With this regimen the author observed 
a very low residual of heart disease. Other investigators reporting a 
low incidence of residual heart disease in patients treated with large 
amounts of steroids for 10-12 weeks include Markowitz and Kuttner, 
1955,14 Roy and Hassell, 1956,22 Ferencz et al., 1959;7 Massell et al., 
1961. 18 
In 1957 Illingworthll published the results of a comparison of 
six treatment groups: (1) no specific treatment; (2) salicylates in 
low dosage; (3) salicylates in high dosage; (4) steroids alone; (5) ster-
oids with salicylates in low dosage; (6) steroids with salicylates in 
high dosages. The study concluded that cortisone was superior to sali-
cylates and that cortisone combined with salicylates, especially in 
high dosage was superior to cortisone alone in the treatment of rheu-
matic fever. However, this study is a retrospective study encompassing 
200 children treated over a period of 9 years. The patients were not 
allotted to the respective treatment groups in a blind random basis and 
were not treated concurrently. Over one-fourth (55) of the children 
were not part of any controlled study, but were blended in with the con-
trolled. The groups were grossly dissimilar numerically ranging from 
61 in the high dosage salicylate group to 16 in the low dosage salicy-
late group. Moreover, the proportion of patients in each of these groups 
with carditis is even more distorted. Evidence of carditis was almost 
exclusively limited to the presence or absence of a murmur and there is 
a notable lack of patients with severe carditis. In summary, this study 
is very interesting but cannot be classified as a valid study. 
Uncontrolled studies reporting that prolonged intensive steroid 
therapy would reduce the incidence of residual rheumatic heart disease 
continued to be published and it became essential to have a concurrent 
group of patients treated with sa1icy1ates. In 1956 the pediatric ser-
vices of 8 hospitals situated in Baltimore, Boston, Cleveland and New 
York combined in a study to compare large doses of prednisone given 12 
weeks with acetylsalicylic acid given for a similar length of time, 
What the study lacked in quantity it compensated in quality. Fifty-seven 
patients were allotted on a blind, random basis to the two treatment 
groups. Only patients with their first rheumatic episode, the onset 
of which was within 28 days and who showed clinical evidence of moderate 
to severe carditis, were admitted to the study. Criteria for the diag-
nosis of carditis were the presence of one or more of the following: 
pericardial rub or effusion, unequivical cardiac enlargement, conges-
tive heart failure, significant aortic or apical diastolic murmurs or 
Grade 3 apical systolic murmurs. Twenty patients were allotted to the 
prednisone group and twenty-eight assigned to the aspirin group. Both 
groups were comparable as to average age, onset to therapy interval and 
cardiac status. Prednisone dosage was 60 mg. daily for three weeks with 
gradual reduction during the following nine weeks. Aspirin was given at 
50 mg/lb daily in divided doses for nine weeks, and then tapered over 
the next three weeks. 
Results obtained by the Combined Study were published in 1960. 2 
At the end of one year follow-up, no significant difference was observed 
in the incidence of residual heart disease in the two treatment groups. 
Furthermore, the study reported that regardless of treatment, the in-
stitution of therapy as late as 20-28 days after onset did not result 
in a higher incidence of residual heart disease. By the same token 
even the prompt control of the acute symptoms did not prevent cardiac 
damage in either treatment groups, However, as was noted in the Coopera-
tive Study, a few patients (4) were changed from aspirin to prednisone 
because of the severity of their manifestations and their lack of re-
sponse to salicylates. Of these four patients, one died.and after,l year 
two had residual heart disease and one had a normal heart. In this 
study the patients were allotted to the two treatment groups on a random 
single blind basis. The decision to transfer these four patients re-
presents clinician bias. The study admitted lithe majority of investi-
gators conducting this study are of the opinion that prednisone sup-
presses the inflammatory reaction of the acute rheumatic attack more 
rapidly than acetylsalicylic acid and in patients with congestive 
heart failure may be life saving. t1 Even though the group felt the 
steroid dosage represented a definite risk, there w,ereno incidents of 
serious untoward reactions to the therapy. 
In contrast to the Combined Study, Dorfman and his associates 5 in 
1961, reported that large doses of steroids continued for 12 weeks 
were more effective than salicylates in the prevention of residual 
heart disease. His study encompassed 131 patients without a history 
of a previous attack and treated within 18 days from the onset of their 
attack, that met the modified Jones criteria. Patients were randomly 
and comparatively distributed into four treatment groups: (1) hydro-
cortisone (2) aspirin (3) hydrocortisone and aspirin (4) no specific 
antirheumatic therapy. As customary, all four groups received penicillin 
prophylaxis and were kept at bed rest as a basic regimen. Patients 
weighing more than 80 Ib received 250 mg. of hydrocortisone each day 
for the first four days; then 100 mg. per day through the eighth week 
after which the dosage was reduced gradually through the twelfth week. 
Those weighing less than 80 Ibs were started on 200 mg., reduced 80 mg. 
and then tapered. Aspirin dosage was determined by blood level as 20 
to 30 mg/100/ml was maintained through nine weeks and then tapered. 
In reviewing Dorfman's study, it becomes apparent that he was 
generally dealing with mild carditis. Although his criteria for car-
ditis is noble, the incidence of pericarditis, congestive failure, 
cardiac enlargement and diastolic murmurs is too small for any critical 
evaluation. In essence, Dorfman has based his findings on the incidence 
of apical systolic murmurs. Of the 85 patients admitted to the study 
wi th "cardi tis" 67 09%) had minimal cardi tis manifes ted only as apical 
systolic murmurs of grade 1 or 2 intensity. It should be recalled that 
the Combined Study required that an apical systolic murmur be of grade 3 
intensity before accepted as sole criteria for carditis. Both studies 
use 1-4 as a basis for gradation. As previously noted and emphasized by 
the U.K. and U.S. Joint Report, patients with mild carditis, irrespective 
of therapy, rarely develop residual heart disease. However, it must be 
conceded that Dorfman's statistics were impressively favorable toward 
steroids in the abolishment of apical systolic murmur during the one year 
follow-up. These murmurs disappeared nearly three times as frequently in 
the groups receiving hormones as opposed to the other regimens. Dorfman's 
data also showed that patients admitted to the study who did not have 
organic murmurs have a low risk of developing them regardless of treat-
ment. Another important fact about this study is that it is one of the 
few controlled studies to actually report serious therapeutic side ef-
fects. Two patients in the aspirin plus steroid group developed bieed-
ing ulcers. 
In an attempt to evaluate the relative merits of the two drugs in 
severe carditis, Czoniczer published a retrospective study in 1964. 4 
As many investigators, Czoniczer felt that the effect of aspirin and 
steroids in preventing residual heart damage could best be judged on 
those patients most likely to develop residual damage. For this reason, 
he selected 145 patients with severe rheumatic carditis as indicated by 
congestive heart failure or pericarditis. Patients were selected from 
admissions to the House of the Good Samaritan between the years of 
1939 and 1963. Needless to say, treatment groups were far from com-
parable. Dosage schedules were variable, selection was not random and 
the groups were not treated concurrently. Many of the aspirin group 
did not receive penicillin therapy or prophylaxis and a larger pro-
portion of the steroid group were observed in their initial attack. 
Czoniczer attempted to minimize the dissimularities of his treatment 
groups through subdivision analysis however, the groups remained 
grossly incompatible. His data the validity of which is questionable, 
indicated a lower death rate and higher recovery rate with steroids. 
Czoniczer concluded that steroids in high dosage were the treatment of 
choice in severe rheumatic carditis. 
Short-term high dosage steriod therapy was introduced by Wilson 
d h k · . f b··· 1953 28- 32 an er co-wor ers ln a serles 0 papers eglnnlng ln • She 
reported that 100 - 160 mg. of prednisone given daily for an average 
of 7 days and instituted early in the course of the disease would 
terminate the rheumatic process and prevent residual heart disease. 
In 1960, she stated, "Our observations clearly demonstrate that in 
patients with progressive clinical symptoms of active carditis, ade-
quate short-term hormone therapy will terminate the inflammatory pro-
cess, significantly shorten the duration, and prevent or minimize 
residual cardiac damage.,,28 However, none of Wilson ISS tudies in-
eluded concurrent observations on patients treated with salicylates 
and her criteria for carditis was subject to much criticism. Neverthe-
less, short-term intensive therapy was very appealing in that serious 
untoward reactions to steroids rarely occur within one or two weeks, 
and the length of hospital stay could be shortened. 
In an attempt to confirm Wilson's result the Combined Rheumatic 
Fever Study Group (1965) undertook a second study in which short term 
3 intensive steroid therapy was compared with aspirin. Seventy-three 
children whose first rheumatic episode had occurred within 21 days of 
the onset therapy and who exhibited moderate to severe carditis were ad-
mitted to the study. Criteria for the carditis was rigid and identical 
to that used in the first Combined Study. Patients were randomly as-
signed to two treatment groups. One group received 3 mg. of predni-
sone per pound of body weight daily up to a maximum of 200 mg/1b/day for 
seven days. The drug was then discontinued without tapering. Patients 
in whom definite signs of active carditis persisted after the seven 
days received a second seven day course with the same dosage. The second 
group received aspirin, 50 mg/1b of body weight daily for six weeks and 
then 25 mg. per pound per day for an additional two weeks. The two 
groups were comparable in most aspects except that more patients with 
congestive heart failure and cardiac enlargement were randomly allotted 
to the aspirin group. Patients were followed for one year after the 
completion of therapy. 
The study was conducted over a four and a half year period. During 
the first two years of the study, three children receiving aspirin were 
transferred to the prednisone group because of the severity of their 
carditis. The investigators realized that this represented a clinical 
bias and accordingly conducted the last two and a half years of the 
study on a double-blind basis. During this period there were no devia-
tions from the prescribed medication. In 1965, the study reported that 
there was no significant difference in the incidence of residual rheuma-
tic heart disease in either the single-blind or the double-blind series. 
Of the 34 patients who received prednisone, 15 still showed signs of 
active carditis after their seven day treatment course. These 15 
patients were given a second seven day course after which 8 of the 
15 again showed active carditis. After one year, more than half of 
the prednisone patients (19 of 34, or 55.8%) had residual rheumatic 
heart disease. Similarly after one year 25 of 39, or 64.1%, of the 
aspirin group had heart disease. The differences between treatment 
groups were small and not statistically significant. 
Obviously, the Combined Study could not confirm Wilson's remark-
able results. We can assume then, that Wilson's loosely constructed 
studies were probably based on patients with mild carditis, the majority 
of whom would not have residual heart damage regardless of therapy. How-
ever, the Combined Study also reported that the high dosage of prednisone 
was well tolerated, rebound phenomena were minimal and no untoward re-
actions were encountered. They further added that it was their clini-
cal impression that "steroids were useful in controlling the exudative 
phase of acute severe myocarditis in critically ill patients. ft Their 
recommendation was that steroids be given to severely ill patients 
with myocarditis for one or two weeks to be followed by aspirin therapy 
for six to eight weeks. 
Perhaps the most recent comparative study is that by Stalzer 
et a124 in which 135 airmen admitted to Warren Air Force Base Hospital 
with rheumatic fever'were evaluated" Patients were randomly assigned 
to aspirin, cortisone and ACTH groups. A 14 month follow-up showed 
that cortisone prevented the appearance of significant murmurs and 
caused the disappearance of existing significant murmurs to a greater 
degree than the other two. However, Stolzer is very careful to deal in 
impressive percentages. Simple computation reveals that at the onset 
of therapy, only 17 of the 135 patients had a carditis and the majority 
of these had a mild carditis. Therefore, little importance can be 
given to the results of this study. 
SUMMARY 
In summarizing the findings of the various reports on rheumatic 
therapy, a statement of Bywaters seems applicable. "Broadly speaking, 
the observers may be grouped as those with enthusiasm but no controls 
"1 
and those with controls and no enthusiasm. However, certain aspects 
have obtained general agreement. First of all, the incidence of car-
ditis in initial attacks of rheumatic fever would seem to be somewhere 
between 40-50%. That is, at least 50% of rheumatic patients do not re-
quire intensive suppressive therapy to prevent residual heart disease. 
With these patients, salicylates remain the treatment of choice. 
Secondly, in those patients with carditis, the most important prog-
nostic factor concerning residual damage is the initial cardiac status 
at the time therapy is instituted. Those patients with severe carditis -
congestive failure, pericarditis or unequivical cardiac enlargement -
have a poor prognosis as approximately 70% will develop residual heart 
disease, irrespective of therapy. Patients with mild or minimal car-
ditis, usually manifest as a grade I or II apical systolic murmur, 
will commonly <75-80%) recover without residual damage regardless of 
therapy. Thirdly, it is generally accepted that neither steroids or 
salicylates alter the duration of a rheumatic attack. Feinstein and 
6 Spagnuolo have conducted extensive studies and concluded that the 
average duration of acute inflammatory activity is 109.::!: 57 days with 
or without treatment. Finally and most importantly, there has been 
no definite or consistent demonstration that cardiac damage is pre-
vented or minimized by either salicylates or steroids given early or 
late in the course of the illness, in high or low dosages, or for 
long or short periods of time. 
From the review presented it should become evident that the 
selection of a suppressive agent can hardly be regarded as critical 
to the outcome of most attacks of rheumatic fever. Steroids and sali-
cylates are palliative but not curative. Both drugs are effective 
anti-inflammatory agents in controlling the toxic manifestations of 
the disease such as fever and arthritis. Steroids are a more potent 
anti-inflammatory agent than aspirin and accordingly clinical observa-
tions have shown that the toxic effects of rheumatic fever are often 
more rapidly controlled with steroids. Not only are steroids more 
promptly effective, but they are also tolerated better than aspirin 
in the acutely ill patient and aften produce a feeling of well being. 
Also instances in which the acute illness failed to respond to sali-
cylates but was subsequently controlled by steroid therapy have been 
well documented. Now keeping in mind that there is no "proof" that 
stero,ids reduce ultimate cardiac scarring, let us propose two practical 
questions. (1) Why would steroids not be likely to have a similar 
prompt suppressive effect on acute edematous myocarditis? It stands 
to reason that the longer an acute infectious process persists the 
more likely residual scarring will result. (2) In a severe carditis 
when the heart is laboring to remian compensated would it not be ad-
vantageous to reduce the added stressful burden of the toxic manifesta-
tions as rapidly as possible? 'rhus, it is the time factor that favors 
steroids. 
What then are the disadvantages of steroid therapy: Namely 
three; (1) side effects, (2) rebound phenomena and paradoxically 
(3) too prompt of a suppression. As has been previously noted, the 
occurrence of Cushingoid cosmetic effects is a common observation 
with prolonged steroid therapy. Varying degree of weight gain, moon-
face, central obesity, "buffalo hump," stria, acne and hirsutism are 
likely to occur if therapy is continued for more than a week or two. 
However, these effects are dosage related and usually disappear within 
several months after cessation of therapy. The major concern is with 
the "serious untoward reactions,,8 to steroid therapy. These include 
adrenal insufficiency, sodium and fluid retention, excess potassium 
excretion, hyperglycemia and glycosuria, ttypertension, psychosis, con-
vulsions, myopathy, osteoporosis with compression fractures of the 
spine, peptic ulcers and the development and spread of bacterial and 
viral infections. 
untoward reactions. 
A review of the controlled study reveals very few 
18 Massell et al treated more than 200 rheumatic 
patients for several weeks with significant doses of steroids and 
reported that serious side effects were infrequent. Furthermore, it 
appears the risk is even further reduced if steroid therapy is short-
term and limited to a 7-10 day period. 3 Aspirin too, is not without 
side effects such as hyperpnea, tinnitus and gastric irritation. 
However, these effects are promptly controlled by dosage reduction, 
and are of less serious nature than steroid reactions. We must con-
clude then that the risk of steroid therapy is small but is a signi-
ficant factor in the selection of a therapeutic regimen. 
The U.K and U.S. Cooperative Study reported that the more prompt 
control of acute manifestations by steroids was balanced by a greater 
tendency for a reappearance of these manifestations following cessa-
tion of treatment. This reactivation has been termed the rebound 
phenomenon. The severity of rheumatic fever during a rebound may be 
as great or greater than at the start of treatment and residual heart 
disease may result. The mechanisms of the rebound phenomenon are 
poorly understood, but it seems likely that an incomplete suppression 
of the rheumatic process is a plausable explanation. This would be 
consistent with the higher incidence of this phenomenon in long-term 
low dosage therapy such as employed in the U. ~ and U. S. study. Re-
bounds were non-existent with the short-term intensive therapy used in 
the Combined Study (1965). Salicylates should be used in the treat-
ment of rebounds as subsequent rebound is less likely after salicylates 
than after steroids. 
A third therapeutic disadvantage is the premature vigorous admini-
stration of suppressive agents before the signs and symptoms of rheuma-
tic fever are unmistakable. Both aspirin and steroids have been in-
23 dicted, but steroids appear to be the greater offender. Stollerman 
points out that "after a well documented streptococcal infection the 
conscientious physician may seek evidence suggestive of rheumatic fever, 
such as persistence of an increased ESR, a prolonged PR interval in 
the electrocardiogram, vague pains in the extremities, borderline tem-
perature elevations, increased intensity of a functional murmur, and 
tachycardia during the physical examination of an anxious or hyperactive 
patient. II The early use of steroids results in an ill defined syndrome, 
only presumptively rheumatic fever, and the subsequent management of 
the patient particularly the indications for long-term prophylaxis is 
in doubt. The emotional burdens that accompany the diagnosis and 
management of rheumatic fever need not be enumerated. Massell and 
co-workers 17 have pOinted out that patients with an acute onset of 
rheumatic fever rarely show a long delay in the appearance of carditis 
if this manifestation is going to occur. In their large series of 
patients, 76 per cent of the patients with evidence of heart damage 
had cardiac involvement during the first week of illness. The five 
year U.K. and U.S, Cooperative Report confirmed Massell's findings and 
added that prognosis is excellent in those patients with initial un-
equivocal evidence of carditis. The diagnosis of acute rheumatic 
fever should therefore be made conservatively and with insistence 
upon clearly expressed major manifestations. 
RECOMMENDATIONS 
Having considered the various aspects of anti-rheumatic therapy 
it now becomes possible to formulate a practical regimen. Bed rest 
and penicillin prophylaxis are very important elements in this re-
gimen, but their discussion is beyond the scope of this paper. 
Aspirin is the drug of choice for patients without rheumatic carditis. 
Aspirin should also be the initial treatment for minimal carditis. 
Markowitz and Kuttner16 define minimal carditis as questionable car-
diac enlargement, apical systolic murmurs of grade 1 or 2, AV disso-
ciation of prolonged PR interval. A dosage of 50 mg. of aspirin 
per pound of body weight administered in six divided doses over 24 
hours will usually result in an adequate blood level (25-35 mg%). 
This dosage should be maintained until a satisfactory clinical response 
is obtained, i.e. until the patient has complete relief of symptoms 
a~d signs of arthritis and the temperature has returned to normal 
range, Such response should occur within one to two weeks at which 
time aspirin may be discontinued and the patient observed for about 
ten days. If there is no recurrence of symptoms, no further therapy 
is needed. In those patients in which fever or arthrit:gs persists or 
recurs, aspirin is continued until all clinical symptoms have subsided. 
However if aspirin does not appear to control the acute manifestations, 
or if carditis becomes more definite, steroid therapy should be con-
sidered. Children usually tolerate aspirin well and small amounts of 
milk may be taken with each dose to reduce gastric irritation. The 
patient should be carefully watched for toxic manifestations such as 
vomiting, tinnitus, and hyperpnea at which time the dosage should be 
reduced appropriately. 
Patients with moderate carditis should receive the benefits of 
short-term steroid therapy. Moderate carditis is arbitrarily defined 
as the presence of grade 3 or louder apical systolic murmur, or an 
aortic diastolic or mitral mid-diastolic murmur of any intensity. The 
dosage of steroid is debatable. The Combined Study (1965) has recom-
mended 1 mg. of predisone per pound of body weight. 21 Rothman has more 
recently pointed out that it is safer to err or the side of high dosage. 
Perhaps then 2 mg/lb of body weight daily would also be acceptable. It 
is purely a matter of clinician preference. The total dosage is divided 
into four equal doses over a 24 hour period and continued until the acute 
stage has subsided, the cardiac signs have stabilized, and the patient's 
general condition has improved. Such a response usually occurs within 
7-10 days at which time the steroid can be discontinued abruptly and 
salicylates begun. Aspirin (50 mg/lb/day) is continued until all clini-
cal and laboratory signs of rheumatic activity have subsided. Predni-
sone is preferred as it tends to cause fewer electrolyte disturbances 
than other steroids. Further minimization of electrolyte imbalance 
is accomplished by using low salt diet. In general. short-term 
steroid therapy is well tolerated and Cushingoid side effects are 
minimal. Similarly, serious untoward effects and rebound phenomena 
are rarely encountered when therapy is limited to a 7-10 day period. 
Cardiac enlargement, pericarditis and congestive failure con-
stitute severe carditis and a direct indication for steroid therapy. 
However, no matter how promptly and completely the acute manifestations 
are suppressed, residual rheumatic heart disease will not be prevented 
in the majority of these patients. Steroids are given primarily in 
hope that they may be life saving. Again this is a clinical impres-
sion and has not been scientifically documented. Severe carditis 
usually requires a somewhat longer course of therapy. Prednisone 
(1-2 mg/lb/day) should be continued for 2-4 weeks. When steroids are 
administered for more than ten days the dose must be tapered before 
discontinuing therapy in order to prevent adrenal insufficiency due 
to endogenous suppression. In these patients, it is advisable to 
overlap the steroid therapy with aspirin for one week before the ster-
oid therapy is stopped so that rebound phenomena are minimized. Aspi-
rin therapy should then be continued until all signs of rheumatic 
activity have disappeared. 
In view of the declining severity of rheumatic fever it is un-
likely that a well controlled prospective study of the value of ster-
oid therapy in critically ill patients with rheumatic carditis will 
be possible in the near future. Even at that, clinician bias is such 
that the random selection of drugs in severely ill patients is gene-
rally thought to be contra-indicated. Perhaps the following comments 
20 by Nadas summarize the current trend of thought. "While a1l this 
(Cooperative Clinical Trial) was going on, members of the study group 
made their own observations without the aid of IBM machines. Other 
investigators throughout the United States, Canada and England drew 
their own conclusions without statisticians, as physicians have done 
since time immemorial. The almost unanimous conclusion was that from 
the clinical view point the hormones were immensely useful indeed." 
A review of the treatment of rheumatic carditis has been pre-
sented. Controlled studies matching the effectiveness of salicylates 
and steroids have been summarized and objectively criticized. Ad-
vantages and limitations of both regimens have been discussed and 
therapeutic recommendations proposed. 
REFERENCES 
1. Bywaters, E. E., et al.: Observations on the treatment of 
rheumatic fever with salicylates, A6!H and cortisone. 
Arthritis Rheum. 1:351, 1958. 
2. Combined Rheumatic Fever Study Group, 1960: A comparison of 
the effect of prednisone and acetylsalicylic acid on the 
incidence of residual rheumatic heart disease. New Eng. 
J. Med. 262:895, 1960. 
3. Combined Rheumatic Fever Study Group, 1965: A comparison of 
short-term, intensive prednisone and acetylsalicylic 
acid therapy in the treatment of acute rheumatic fever. 
New Eng. J. Med. 272:63, 1965. 
4. Czoniczer, G.; Amezuca, F.; Pelargonio, S.; and Massell, B. F.: 
Therapy of severe rheumatic carditis: Comparison of adreno-
cortical steroids and aspirin. Circulation 29:813, 1964. 
5. Dorfman, Ao; Gross, J.Io; and Lorinez, A. E.: The treatment 
of acute rheumatic fever. Pediatrics 27:692, 1961. 
6. Feinstein, A. R. and Spagnuolo, M.: The duration of activity 
in acute rheumatic fever o J.A.M.A. 175:1117, 1961. 
7. Ferencz, C.; Markowitz, M.; and Bunim, J. J.: The effect of 
large doses of prednisone on acute rheumatic fever. Ob-
servations on the treatment of seventeen patients with 
carditis with a two year follow-up. Amer. J. Dis. Child. 
97:561, 1959. 
8. Good, R. A.; Vernier, R.L.; and Smith, R. T.: Serious untoward 
reactions to therapy with cortisone and adrenocorticotropin 
in pediatric practice. I. and I. Pediatrics 19:95 and 272, 
19570 
9. Greenman, L.; Weigand, R. A.; and Danowski, I. S.: Cortisone 
therapy in initial attacks of rheumatic carditis. Ann. Rheum. 
Dis. 12:342, 1953. 
10. Hench, P. S.; Slocumb, C. H.; Barnes, A. R.; Smith, H. L.; Polley, 
H. F.; and Kendall, E. C.: Effects of adrenal cortical hor-
mone l7-hydroxy-ll-dehydrocorticosterone (Compound E) on 
acute phase of rheumatic fever: Preliminary report. Proc. 
Mayo Clin. 24:277, 1949. 
11. Illingworth, R. S.; Lober, J.; Holt, K. S.; Rendle-Short, J.; 
Jowett, G. H.; and Gibson, W. M.: Acute rheumatic fever 
in children. A comparison of six forms of treatment in 
200 cases. Lancet 2:653, 1957. 
12. Kuttner, A. G.: Current status of steroid therapy in rheumatic 
fever. Amer. Heart J. 70:147, 1965. 
13. Maclagan, T.: The treatment of acute rheumatisn by Salicin. 
Lancet 1:342, 1876. 
14. Markowitz, M. and Kuttner, A. G.: The effect of intensive and 
prolonged therapy with cortisone and hydrocortisone in 
first attacks of rheumatic carditis. Pediatrics 16:325, 
1955. 
15. Markowitz, M and Kuttner, A. G.: Treatment of a cute rheumatic 
fever. Amer. J. Dis. Child. 104:313, 1962. 
REFERENCES 
16 0 Markowitz, A. and Kuttner, A. G.: Rheumatic Fever; Diagnosis, 
Management and Preventh:m. Wo B. Saunders Co., Philadel-
phia, 1965. 
17. Massell, B. F.: The diagnosis and treatment of rheumatic fever 
and rheumatic carditis. Med. Clin. N. Amer. 42:1343, 1958. 
18. Massell, Bo F.; Jhaveri, S.; Czoniczer, G.; and Barnet, R.: 
Treatment of rheumatic fever and rheumatic carditis. Ob-
servations providing a basis for the selection of aspirin 
or adrenocortical steroids. Med. Clin. N. Amer. 45:1349, 
1961. 
19. Mayer, Fo E.; Doyle, E. F.; Herrera, L.; and Brownell, K. D.: 
Declining severity of first attack of rheumatic fever. Amer. 
J. Dis. Dhild. 105:146, 1963. 
20. Nadas, A. S.: Pediatric Cardiology. Second Ed. Philadelphia, 
W. B. Saunders Co., 1963, p.186. 
21. Rothman, P. E.: Treatment of rheumatic carditis. Clin. Pediat-
rics 4:619, 1965. 
22, Roy, S. B. and Massell, B. F.: Comparison of large and small 
doses of hormones in the treatment of acute rheumatic cardi-
tis. Circulation 14:44, 1956. 
23. Stollerman, G. H.: Treatment and prevention of rheumatic fever 
and rheumatic heart disease. Pede Clin. N. Amer. 11:213, 
1964. 
24. Stolzer, B. L.; Houser, H.B.; and Clark, C. J.: Therapeutic 
agents in rheumatic carditis. Arch. Int. Med., 95:677, 1955. 
25. U. K. and U. S. Joint Report: The treatment of acute rheumatic 
fever in children: Cooperative clinical trial of ACTH, cor-
tisone and asp~r~n. Circulation 11:343, 1955. 
26. U. K. and U. S. Joint Report: The evolution of rheumatic heart 
disease in children: Five year report of a cooperative 
clinical trial of ACTH, cortisone and aspirin. Circulation 
22:503, 1960. 
27. U. K. and U. S. Joint Report: The natural history of rheumatic 
fever and rheumatic heart disease: Ten year report of a 
cooperative clinical trial of ACTH, cortisone and aspirin. 
Circulation 32:457, 1965. 
28. Wilson, M. G.: Present status of hormone therapy in rheumatic 
fever with special reference to short-term treatment in 
active carditis. Advances Pediat. 11:243, 1960. 
290 Wilson, M. G.: Advances in Rheumatic Fever, 1940-1961. Harper 
and Row, New York, 1962. 
30. Wilson, M. G.; Helper, H. N.; Lubschez, R.; Hain, K.; and 
Epstein,N.: Effect of short-term administration of corti-
cotropin in active rheumatic carditis. A.M.A. Amer. J. Dis. 
Child. 86:131, 1953. 
31. Wilson, M. G. and Lim, W. N.: Natural course of active rheumatic 
carditis and evaluation of hormone therapy. J.A.M.A. 160:1457, 
1956. 
32. Wilson, M. G. and Lim, W. N.: Short-term hormone therapy: Its 
effect in active rheumatic carditis of varying duration. New 
Eng. J. Med. 260:802, 1959. 
